GWSG
RGNX icon

GPS Wealth Strategies Group’s Regenxbio RGNX Stock Holding History

GPS Wealth Strategies Group’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13
Closed -$233 – 1292
2023
Q4 		$233 Hold
13
– – ﹤0.01% 1210
2023
Q3 		$214 Buy
+13
New +$236 ﹤0.01% 1242

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

GPS Wealth Strategies Group's RGNX Position: Q1 2024 in Review

GPS Wealth Strategies Group sold out of Regenxbio (RGNX) in Q1 2024, closing a stake of 13 shares — an estimated $233 sold.

GPS Wealth Strategies Group first reported a position in RGNX in Q3 2023 and held it in 2 quarters. The position peaked at $233 in Q4 2023. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2024.

  • GPS Wealth Strategies Group reported no remaining Regenxbio position as of Q1 2024 after selling out during the quarter.
  • GPS Wealth Strategies Group sold 13 Regenxbio shares in Q1 2024, an estimated $233.
  • GPS Wealth Strategies Group first reported a position in Regenxbio in Q3 2023 and held it in 2 quarters.
  • GPS Wealth Strategies Group's Regenxbio position peaked at $233 in Q4 2023.
  • 188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2024.

Based on GPS Wealth Strategies Group's 13F filing for Q1 2024, filed 30 Apr 2024.